
Ocugen, Inc. (OCGN) Stock Forecast & Price Target
Ocugen, Inc. (OCGN) Analyst Ratings
Bulls say
Ocugen is a promising company with a positively reviewed gene therapy pipeline aimed at addressing unmet medical needs in the retinal disease space. While there may be a potential delay in their Stargardt program, the company has shown strong results in their Phase 2 trials, with a 31% reduction in lesion area and 27% reduction in EZ loss. With a planned pivotal trial in 2026 and potential expedited approval pathways, Ocugen's stock is positioned for growth in the long term, making it a strong investment opportunity for those interested in the biotech sector.
Bears say
Ocugen is a clinical-stage company with a negative outlook on its stock due to its unproven and untested pipeline and high levels of debt. Despite lowering their 12-month price target to $9.50 per diluted share, the company's lack of revenue and high financial risk raises concerns about their ability to successfully bring their products to market. The potential for unexpected safety issues during clinical trials further adds to the uncertainty and risk associated with investing in Ocugen.
This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.
Ocugen, Inc. (OCGN) Analyst Forecast & Price Prediction
Start investing in Ocugen, Inc. (OCGN)
Order type
Buy in
Order amount
Est. shares
0 shares